Abstract
ABSTRACT Purpose Although FOLFIRINOX has become one of the standard option for the treatment of aPDAC, tolerability and safety issues, with particular regard to hematologic toxicity and increased risk of AE in pts carrying biliary stents, may represent a barrier for the routinely adoption in clinical practice. Methods The clinical reports of 36 aPDAC pts undergone 1st-line FOLFIRINOX in 2 different institutions were reviewed. Toxicities, activity and efficacy were determined according to 1) primary G-CSF prophylaxis (dd 7-9-11; yes/no 21/15 pts), and 2) presence/absence biliary stent. Results Pts characteristics: N°: 36; cycles: 241, M/F: 22/14; median age: 57 yrs [range 37-70]; ECOG PS 0/1: 33/3; stage III/IV: 10/26. G3/4 toxicity occurred in 50% reduction in CA19.9. Conclusions These data indicate that FOLFIRINOX seems to be well tolerated and easily manageable in young ( Disclosure All authors have declared no conflicts of interest.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
